Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GVAX, Nivolumab, and SBRT in Borderline Resectable Pancreatic Cancer
NCT03161379Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Feb 2018
- Primary completion
- Feb 2024
- Countries
- 1
01
Overview
Phase 2, open-label trial of GVAX pancreatic cancer vaccine in pancreatic adenocarcinoma (PDAC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: CD8+ T Cell Density in Tumor Tissue at 2 months. Started Feb 2018; status: completed.
02
Drugs
GVAX pancreatic cancer vaccine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03161379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03161379.